80 FR 10656 - Possession, Use, and Transfer of Select Agents and Toxins; Biennial Review
DEPARTMENT OF HEALTH AND HUMAN SERVICES Federal Register Volume 80, Issue 39 (February 27, 2015)
Federal Register Volume 80, Issue 39 (February 27, 2015)
| Page Range | 10656-10658 | |
| FR Document | 2015-04169 |
[Federal Register Volume 80, Number 39 (Friday, February 27, 2015)] [Proposed Rules] [Pages 10656-10658] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-04169] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES 42 CFR Part 73 [Docket No. CDC-2015-0006] RIN 0920-AA59 Possession, Use, and Transfer of Select Agents and Toxins; Biennial Review AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Advance notice of proposed rulemaking and request for comments. ----------------------------------------------------------------------- SUMMARY: In accordance with the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, Subtitle A (Department of Health and Human Services) of Title II (Enhancing Controls on Dangerous Biological Agents and Toxins) of Public Law 107-188 (June 12, 2002) (the Bioterrorism Response Act), the Centers for Disease Control and Prevention (CDC) located within the Department of Health and Human Services (HHS) has initiated the review of the HHS list of biological agents and toxins that have the potential to pose a severe threat to public health and safety. We are considering whether to propose amending the HHS list by removing six biological agents. DATES: Comments should be received on or before April 28, 2015. ADDRESSES: You may submit comments, identified by Regulation Identifier Number (RIN), 0920-AA59 or Docket Number CDC-2015-0006 in the heading of this document by any of the following methods:Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments. Mail: Centers for Disease Control and Prevention, Select Agent Program, 1600 Clifton Road NE., Mailstop A-46, Atlanta, Georgia 30329, ATTN: RIN 0920-AAxx. Instructions: All submissions received must include the agency name and RIN for this rulemaking. All relevant comments received will be posted without change to http://www.regulations.gov, including any personal information provided. Docket Access: For access to the docket to read background documents or comments received or to download an electronic version of the ANPRM, go to http://www.regulations.gov. Comments will be available for public inspection Monday through Friday, except for legal holidays, from 9 a.m. until 5 p.m. at 1600 Clifton Road NE., Atlanta, GA 30329. Please call ahead to 1-866-694-4867 and ask for a representative in the Division of Select Agents and Toxins to schedule your visit. Please be aware that comments and other submissions from members of the public are made available for public viewing without changes. FOR FURTHER INFORMATION CONTACT: Robbin Weyant, Director, Division of Select Agents and Toxins, Centers for Disease Control and Prevention, 1600 Clifton Road NE., Mailstop A-46, Atlanta, Georgia 30329. Telephone: (404) 718-2000. SUPPLEMENTARY INFORMATION: The Preamble to this notice of proposed rulemaking is organized as follows: I. Public Participation II. Background III. Changes to 42 CFR Part 73, Modifications to the List of Select Agents and Toxins Being Considered A. Coxiella burnetii B. Rickettsia prowazekii C. Bacillus anthracis Pasteur strain D. Brucella abortus, B. melitensis, and B. suis IV. References I. Public Participation Interested persons or organizations are invited to participate in this rulemaking by submitting written views, recommendations, and data. Comments are invited on any topic related to this rulemaking. In addition, HHS/CDC invites comments specifically as to whether there are biological agents or toxins that should be added or removed from the HHS list of select agents and toxins based on the following criteria, or any other appropriate criteria: (1) The effect on human health of exposure to the agent or toxin; (2) The degree of contagiousness of the agent or toxin and the methods by which the agent or toxin is transferred to humans; and (3) The availability and effectiveness of pharmacotherapies and immunizations to treat and prevent any illness resulting from infection by the agent or exposure to the toxin. (4) The needs of children and other vulnerable populations. Comments received, including attachments and other supporting materials, are part of the public record and subject to public disclosure. Do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. HHS/CDC will carefully consider all comments submitted in preparation of a proposed final rule. II. Background The Bioterrorism Response Act requires the HHS Secretary to establish by regulation a list of biological agents and toxins that have the potential to pose a severe threat to public health and safety. In determining whether to include an agent or toxin on the list, the HHS Secretary considers criteria such as the effect on human health of exposure to an agent or toxin; the degree of contagiousness of the agent and the methods by which the agent or toxin is transferred to humans; the availability and effectiveness of pharmacotherapies and immunizations to treat and prevent illnesses resulting from an agent or toxin; and the needs of children and other vulnerable populations. The current list of HHS select agents and toxins can be found at 42 CFR 73.3 (HHS select agents and toxins) and 42 CFR 73.4 (Overlap select agents and toxins). The list of HHS and Overlap [[Page 10657]] select agents and toxins is available at: http://www.selectagents.gov/Select%20Agents%20and%20Toxins%20List.html. The HHS Secretary last republished the list of HHS select agents and toxins in the Federal Register on October 5, 2012 (77 FR 61084). The list of HHS select agents and toxins is divided into two sections. The select agents and toxins listed in Sec. 73.3 (HHS select agents and toxins) are those regulated only by HHS under the authority of the Bioterrorism Response Act (42 U.S.C. 262a). The select agents and toxins listed in Sec. 73.4 (Overlap select agents and toxins) are those regulated by HHS under the authority of the Bioterrorism Response Act and regulated by the U.S. Department of Agriculture under the authority of the Agricultural Bioterrorism Protection Act of 2002 (7 U.S.C. 8401). The Bioterrorism Response Act requires the HHS Secretary to review and republish the list of select agents and toxins on at least a biennial basis. Using government subject matter experts, HHS/CDC conducts the biennial review process in consultation with the HHS/CDC Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC). The ISATTAC recommends changes to the list of HHS select agents and toxins. The ISATTAC is comprised of Federal government employees from CDC, Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response, the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Department of Homeland Security (DHS), the Department of Defense (DOD), the USDA/Animal and Plant Health Inspection Service (APHIS), USDA/Agricultural Research Service (ARS), and USDA/CVB (Center for Veterinary Biologics). Based on the criteria outlined in the Bioterrorism Response Act, the ISATTAC used the following measures in its review: the degree of pathogenicity (ability of an organism to cause disease), communicability (ability to spread from infected to susceptible hosts), ease of dissemination, route of exposure, environmental stability, ease of production, ability to genetically manipulate or alter, long-term health effects, acute morbidity (illness), acute mortality (death), available treatment, status of host immunity, vulnerability of special populations, and the burden or impact on the health care system. III. Proposed Changes to 42 CFR Part 73, Modifications to the List of Select Agents and Toxins Being Considered The purpose of this advanced notice of proposed rulemaking is to seek public comment on the appropriateness of the current list of HHS and Overlap select agents and toxins. Specifically, we are providing an opportunity for interested persons to submit comments, research data, and other information that will better inform us as to whether: (1) There are any other biological agents or toxins that should be added to the list because they have the potential to pose a severe threat to public health and safety; (2) there are any other biological agents or toxins currently on the list that should be removed because they no longer have the potential to pose a severe threat to public health and safety, and/or (3) the biological agents specifically listed in the following paragraphs should be removed or remain on the list. HHS/CDC is also seeking comments on the following considerations regarding the list of HHS and Overlap select agents: A. Coxiella burnetii Coxiella burnetii causes a disease called Q fever. Q fever is an acute febrile rickettsial disease that varies in severity and duration. Should Coxiella burnetii be removed or retained as a HHS select agent? Are there other reasons or research data to support the removal besides the following reasons? It is not easily transmitted from person to person (1); It has a low mortality rate with antibiotic treatment (2); and There is an investigational new drug (IND) vaccine available for at-risk personnel (3). B. Rickettsia prowazekii Rickettsia prowazekii causes epidemic typhus. Epidemic typhus is a potentially lethal, louse-borne, disease caused by R. prowazekii. Should Rickettsia prowazekii be removed or retained as a HHS select agent? Are there other reasons or research data to support the removal besides the following reasons? It is readily treatable with antibiotics (4); The risk of mass casualties is low because R. prowazekii can be treated with a single dose of doxycycline when symptoms are present (4); and Transmissibility from person to person is low due to the fact that R. prowazekii is usually transmitted via blood, although it can be spread through inhalation of louse feces. C. Bacillus anthracis Pasteur Strain Bacillus anthracis is the bacterium that causes anthrax, an acute disease in animals and humans. However, different strains of B. anthracis have different abilities to cause disease. The Pasteur strain, for example, is unable to produce toxic factors and is not considered harmful to humans. Should B. anthracis Pasteur strain be removed or retained as an Overlap select agent? Are there other reasons or research data to support the removal besides the following reasons? B. anthracis Pasteur strain lacks the plasmid that encodes the toxin genes causing disease (6); B. anthracis Sterne strain, which lacks the plasmid that encodes for the capsule, was excluded from the requirements of the regulations effective on February 27, 2003 (7-8); and Historically, the B. anthracis Pasteur strain has been retained as a select agent to allow for continued oversight of laboratories in which the accidental (or intentional) combination of this strain with the Sterne strain could occur to produce de novo the wild type phenotype B. anthracis. However, a recent study indicates that bacterial transformation of B. subtilis with plasmid DNA (e.g. pXO1 into Bacillus anthracis Pasteur strain) is inefficient; indicating that transformation with bacteria such as B. anthracis would also be inefficient (9). D. Brucella abortus, B. melitensis, and B. suis Brucella abortus, B. melitensis, and B. suis bacteria cause brucellosis, a disease that can spread from animals to humans. Should B. abortus, B. melitensis, and B. suis be removed or retained as select agents? Are there other reasons or research data to support the removal besides the following reasons? B. abortus has a low human mortality rate (10); B. abortus, B. melitensis, and B. suis are readily treatable with antibiotics (10); and Human-to-human transmission is extremely rare, and wildlife carriers in the United States often come into contact with humans without significant transmission (10). IV. References 1. T.J. Marrie. Q fever. In: Marrie TJ, editor. Q fever. Vol. 1. Boca Raton, FL: CRC Press; 1990. (The disease). 2. M. Maurin and D. Raoult. Q fever. Clin Microbiol Rev. Oct. 1999;12(4):518-53. 3. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition, http://www.cdc.gov/biosafety/ [[Page 10658]] publications/bmbl5/BMBL5_sect_VIII_d.pdf. 4. D. Raoult, J.B. Ndihokubwayo, H. Tissot-Dupont, V. Roux, B. Faugere, R. Abegbinni, and R.J. Birtles. Outbreak of epidemic typhus associated with trench fever in Burundi. The Lancet. Aug. 1998; 352 (3125):353-358. 5. D. Raoult, T. Woodward, and J.S. Dumler. The history of epidemic typhus. Infect Dis Clin N Am. Mar. 2004; 18(1):127-140. 6. B.E. Ivins, J.W. Ezzell, J. Jemski, K.W. Hedlund, J.D. Ristroph, and S.H. Leppla. Immunization Studies with Attenuated Strains of Bacillus anthracis. Infection and Immunity. May 1986; 52(2):454-458. 7. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases ``Anthrax Sterne strain (34F2) of Bacillus anthracis,'' http://www.cdc.gov/nczved/divisions/dfbmd/diseases/anthrax_sterne/. 8. Federal Select Agent Program, ``Select Agents and Toxins Exclusions,'' http://www.selectagents.gov/SelectAgentsandToxinsExclusions.html. 9. C. Johnston, B. Martin, G. Fichant, P. Polard, and J.P. Claverys. Bacterial transformation: distribution, shared mechanisms and divergent control. Nature Rev. Microbiol. 2014; 12: 181-196. 10. Center for Food Security and Public Health, ``Brucellosis Technical fact sheet,'' http://www.cfsph.iastate.edu/Factsheets/pdfs/brucellosis.pdf. Dated: February 5, 2015. Sylvia M. Burwell, Secretary. [FR Doc. 2015-04169 Filed 2-26-15; 8:45 am] BILLING CODE 4163-18-P
![10656 Federal Register / Vol. 80, No. 39 / Friday, February 27, 2015 / Proposed Rules
Wynkoop Street, Denver, Colorado Agents and Toxins) of Public Law 107– B. Rickettsia prowazekii
80202–1129, 303–312–6145, 188 (June 12, 2002) (the Bioterrorism C. Bacillus anthracis Pasteur strain
morrison.kendra@epa.gov. Response Act), the Centers for Disease D. Brucella abortus, B. melitensis, and B.
Control and Prevention (CDC) located suis
SUPPLEMENTARY INFORMATION: In the IV. References
‘‘Rules and Regulations’’ section of this within the Department of Health and
Federal Register, EPA is publishing Human Services (HHS) has initiated the I. Public Participation
these negative declarations as a direct review of the HHS list of biological Interested persons or organizations
final rule without prior proposal agents and toxins that have the potential are invited to participate in this
because the Agency views this as a to pose a severe threat to public health rulemaking by submitting written views,
noncontroversial action and anticipates and safety. We are considering whether recommendations, and data. Comments
no adverse comments. A detailed to propose amending the HHS list by are invited on any topic related to this
rationale for publication is set forth in removing six biological agents. rulemaking.
the preamble to the direct final rule. If DATES: Comments should be received on In addition, HHS/CDC invites
EPA receives no adverse comments, or before April 28, 2015. comments specifically as to whether
EPA will not take further action on this ADDRESSES: You may submit comments, there are biological agents or toxins that
proposed rule. If EPA receives adverse identified by Regulation Identifier should be added or removed from the
comments, EPA will withdraw the Number (RIN), 0920–AA59 or Docket HHS list of select agents and toxins
direct final rule and it will not take Number CDC–2015–0006 in the heading based on the following criteria, or any
effect. EPA will address all public of this document by any of the following other appropriate criteria:
comments in a subsequent final rule methods: (1) The effect on human health of
based on this proposed rule. EPA will • Federal eRulemaking Portal: http:// exposure to the agent or toxin;
not institute a second comment period www.regulations.gov. Follow the (2) The degree of contagiousness of
on this action. Any parties interested in instructions for submitting comments. the agent or toxin and the methods by
commenting must do so at this time. • Mail: Centers for Disease Control which the agent or toxin is transferred
Please note that if EPA receives adverse and Prevention, Select Agent Program, to humans; and
comment on an amendment, paragraph, 1600 Clifton Road NE., Mailstop A–46, (3) The availability and effectiveness
or section of this rule and if that Atlanta, Georgia 30329, ATTN: RIN of pharmacotherapies and
provision may be severed from the 0920–AAxx. immunizations to treat and prevent any
remainder of the rule, EPA may adopt Instructions: All submissions received illness resulting from infection by the
as final those provisions of the rule that must include the agency name and RIN agent or exposure to the toxin.
are not the subject of an adverse for this rulemaking. All relevant (4) The needs of children and other
comment. See the information provided comments received will be posted vulnerable populations.
in the Direct Final action of the same without change to http:// Comments received, including
title which is located in the Rules and www.regulations.gov, including any attachments and other supporting
Regulations Section of this Federal personal information provided. materials, are part of the public record
Register. Docket Access: For access to the and subject to public disclosure. Do not
Authority: 42 U.S.C. 7401 et seq. docket to read background documents include any information in your
or comments received or to download comment or supporting materials that
Dated: January 30, 2015. an electronic version of the ANPRM, go you consider confidential or
Debra H. Thomas, to http://www.regulations.gov. inappropriate for public disclosure.
Acting Regional Administrator, Region 8. Comments will be available for public HHS/CDC will carefully consider all
[FR Doc. 2015–03921 Filed 2–26–15; 8:45 am] inspection Monday through Friday, comments submitted in preparation of a
BILLING CODE 6560–50–P except for legal holidays, from 9 a.m. proposed final rule.
until 5 p.m. at 1600 Clifton Road NE.,
Atlanta, GA 30329. Please call ahead to II. Background
DEPARTMENT OF HEALTH AND 1–866–694–4867 and ask for a The Bioterrorism Response Act
HUMAN SERVICES representative in the Division of Select requires the HHS Secretary to establish
Agents and Toxins to schedule your by regulation a list of biological agents
42 CFR Part 73 visit. Please be aware that comments and toxins that have the potential to
[Docket No. CDC–2015–0006]
and other submissions from members of pose a severe threat to public health and
the public are made available for public safety. In determining whether to
RIN 0920–AA59 viewing without changes. include an agent or toxin on the list, the
FOR FURTHER INFORMATION CONTACT: HHS Secretary considers criteria such as
Possession, Use, and Transfer of
Robbin Weyant, Director, Division of the effect on human health of exposure
Select Agents and Toxins; Biennial
Select Agents and Toxins, Centers for to an agent or toxin; the degree of
Review
Disease Control and Prevention, 1600 contagiousness of the agent and the
AGENCY: Centers for Disease Control and Clifton Road NE., Mailstop A–46, methods by which the agent or toxin is
Prevention (CDC), Department of Health Atlanta, Georgia 30329. Telephone: transferred to humans; the availability
and Human Services (HHS). (404) 718–2000. and effectiveness of pharmacotherapies
ACTION: Advance notice of proposed SUPPLEMENTARY INFORMATION: The and immunizations to treat and prevent
tkelley on DSK3SPTVN1PROD with PROPOSALS
rulemaking and request for comments. Preamble to this notice of proposed illnesses resulting from an agent or
rulemaking is organized as follows: toxin; and the needs of children and
SUMMARY: In accordance with the Public other vulnerable populations. The
I. Public Participation
Health Security and Bioterrorism II. Background
current list of HHS select agents and
Preparedness and Response Act of 2002, III. Changes to 42 CFR Part 73, Modifications toxins can be found at 42 CFR 73.3
Subtitle A (Department of Health and to the List of Select Agents and Toxins (HHS select agents and toxins) and 42
Human Services) of Title II (Enhancing Being Considered CFR 73.4 (Overlap select agents and
Controls on Dangerous Biological A. Coxiella burnetii toxins). The list of HHS and Overlap
VerDate Sep<11>2014 16:15 Feb 26, 2015 Jkt 235001 PO 00000 Frm 00030 Fmt 4702 Sfmt 4702 E:\FR\FM\27FEP1.SGM 27FEP1](https://thefederalregister.org/doc/80_FR_10695/page/1.svg)
![10658 Federal Register / Vol. 80, No. 39 / Friday, February 27, 2015 / Proposed Rules
publications/bmbl5/BMBL5_sect_VIII_ ADDRESSES: You may submit comments, requirements for recipients of funding
d.pdf. identified by WC Docket Nos. 10–90 and awarded through the Phase II
4. D. Raoult, J.B. Ndihokubwayo, H. Tissot- 14–259, by any of the following competitive bidding process. Thus,
Dupont, V. Roux, B. Faugere, R. methods: during the comment period established,
Abegbinni, and R.J. Birtles. Outbreak of
epidemic typhus associated with trench
• Electronic Filers: Comments may be the Bureau encourages parties to
fever in Burundi. The Lancet. Aug. 1998; filed electronically using the Internet by comment on the petitions’ LOC
352 (3125):353–358. accessing the ECFS: http:// proposals more generally and their
5. D. Raoult, T. Woodward, and J.S. Dumler. fjallfoss.fcc.gov/ecfs2/. potential applicability to the Phase II
The history of epidemic typhus. Infect • People with Disabilities: Contact the competitive bidding process.
Dis Clin N Am. Mar. 2004; 18(1):127– FCC to request reasonable 3. In order to develop a complete
140. accommodations (accessible format record on the issues presented in the
6. B.E. Ivins, J.W. Ezzell, J. Jemski, K.W. documents, sign language interpreters, waiver petition, the request for more
Hedlund, J.D. Ristroph, and S.H. Leppla. CART, etc.) by email: FCC504@fcc.gov general comment will be treated, for ex
Immunization Studies with Attenuated parte purposes, as ‘‘permit-but-disclose’’
Strains of Bacillus anthracis. Infection
or phone: 202–418–0530 or TTY: 202–
418–0432. in accordance with section 1.1200(a) of
and Immunity. May 1986; 52(2):454–458.
7. Centers for Disease Control and For detailed instructions for the Commission’s rules, subject to the
Prevention, National Center for Emerging submitting comments and additional requirements under section 1.1206(b).
and Zoonotic Infectious Diseases information on the rulemaking process, II. Procedural Matters
‘‘Anthrax Sterne strain (34F2) of Bacillus see the SUPPLEMENTARY INFORMATION
anthracis,’’ http://www.cdc.gov/nczved/ section of this document. 1. Initial Regulatory Flexibility Act
divisions/dfbmd/diseases/anthrax_
FOR FURTHER INFORMATION CONTACT:
Analysis
sterne/.
Heidi Lankau, Wireline Competition 4. The USF/ICC Transformation Order
8. Federal Select Agent Program, ‘‘Select
Agents and Toxins Exclusions,’’ http:// Bureau at (202) 418–7400 or TTY (202) and FNPRM included an Initial
www.selectagents.gov/ 418–0484. Regulatory Flexibility Analysis (IRFA)
SelectAgentsandToxinsExclusions.html. SUPPLEMENTARY INFORMATION: This is a pursuant to 5 U.S.C. 603, exploring the
9. C. Johnston, B. Martin, G. Fichant, P. synopsis of the Wireline Competition potential impact on small entities of the
Polard, and J.P. Claverys. Bacterial Bureau’s Public Notices (Notices) in WC Commission’s proposal. We invite
transformation: distribution, shared parties to file comments on the IRFA in
Docket No. 10–90, 14–259; DA 15–140,
mechanisms and divergent control. light of this additional notice.
Nature Rev. Microbiol. 2014; 12: 181– released January 30, 2015 and DA 15–
196. 158, released February 4, 2015. The 2. Initial Paperwork Reduction Act of
10. Center for Food Security and Public complete text of these documents are 1995 Analysis
Health, ‘‘Brucellosis Technical fact available for inspection and copying 5. This document seeks comment on
sheet,’’ http://www.cfsph.iastate.edu/ during normal business hours in the a potential new or revised information
Factsheets/pdfs/brucellosis.pdf. FCC Reference Information Center, collection requirement. If the
Dated: February 5, 2015. Portals II, 445 12th Street SW., Room Commission adopts a new or revised
Sylvia M. Burwell, CY–A257, Washington, DC 20554. The information collection requirement, the
Secretary. document may also be purchased from Commission will publish a separate
the Commission’s duplicating notice in the Federal Register inviting
[FR Doc. 2015–04169 Filed 2–26–15; 8:45 am]
contractor, Best Copy and Printing, Inc., the public to comment on the
BILLING CODE 4163–18–P
445 12th Street SW., Room CY–B402, requirement, as required by the
Washington, DC 20554, telephone (800) Paperwork Reduction Act of 1995,
378–3160 or (202) 863–2893, facsimile Public Law 104–13 (44 U.S.C. 3501–
FEDERAL COMMUNICATIONS (202) 863–2898, or via Internet at 3520). In addition, pursuant to the
COMMISSION http://www.bcpiweb.com. Small Business Paperwork Relief Act of
47 CFR Part 54 I. Introduction 2002, Public Law 107–198, see 44 U.S.C.
3506(c)(4), the Commission seeks
1. On January 27, 2015, the Alliance specific comment on how it might
[WC Docket No. 10–90, 14–259; DA 15–140;
of Rural Broadband Applicants filed a ‘‘further reduce the information
DA 15–158]
petition for limited waiver of certain collection burden for small business
Wireline Competition Bureau Seeks letter of credit (LOC) requirements concerns with fewer than 25
Comment More Generally on Letter of applicable to the rural broadband employees.’’
Credit Proposals for Connect America experiments. On February 3, 2015,
Phase II Competitive Bidding Process NTCA—The Rural Broadband 3. Filing Requirements
Association filed an emergency petition 6. Pursuant to §§ 1.415 and 1.419 of
AGENCY: Federal Communications for limited waiver of the LOC bank the Commission’s rules, 47 CFR 1.415,
Commission. eligibility requirements applicable to 1.419, interested parties may file
ACTION: Proposed rule. the rural broadband experiments. On comments and reply comments on or
January 21, 2015, the National Rural before the dates indicated on the first
SUMMARY: In these documents, the Utilities Cooperative Finance page of this document. Comments may
Wireline Competition Bureau seeks Corporation and its affiliate, the Rural be filed using the Commission’s
comment more generally on letter of
tkelley on DSK3SPTVN1PROD with PROPOSALS
Telephone Finance Cooperative, also Electronic Comment Filing System
credit proposals raised by several filed a petition for waiver of one aspect (ECFS). See Electronic Filing of
petitions for waiver and their potential of the Commission’s LOC bank Documents in Rulemaking Proceedings,
applicability to the Phase II competitive eligibility requirements. 63 FR 24121 (1998).
bidding process. 2. The Bureau notes that these • Electronic Filers: Comments may be
DATES: Comments are due on or before petitions for waiver raise issues that filed electronically using the Internet by
March 30, 2015 and reply comments are may be relevant to broader pending accessing the ECFS: http://
due on or before April 13, 2015. questions regarding possible LOC fjallfoss.fcc.gov/ecfs2/.
VerDate Sep<11>2014 16:15 Feb 26, 2015 Jkt 235001 PO 00000 Frm 00032 Fmt 4702 Sfmt 4702 E:\FR\FM\27FEP1.SGM 27FEP1](https://thefederalregister.org/doc/80_FR_10695/page/3.svg)
Document Created: 2015-12-18 13:14:14
Document Modified: 2015-12-18 13:14:14
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Proposed Rules | |
| Action | Advance notice of proposed rulemaking and request for comments. | |
| Dates | Comments should be received on or before April 28, 2015. | |
| Contact | Robbin Weyant, Director, Division of Select Agents and Toxins, Centers for Disease Control and Prevention, 1600 Clifton Road NE., Mailstop A-46, Atlanta, Georgia 30329. Telephone: (404) 718-2000. | |
| FR Citation | 80 FR 10656 | |
| RIN Number | 0920-AA59 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR